The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initial results of two phase I trials delivering mbIL-21 ex vivo expanded haploidentical NK cells after fludarabine/cytarabine for patients with relapsed/refractory myeloid leukemias.
 
Stefan O. Ciurea
Stock and Other Ownership Interests - CytoSen
Consulting or Advisory Role - Kiadis Pharma; MolMed; Spectrum Pharmaceuticals
 
Lucia Silla
No Relationships to Disclose
 
Kai Cao
No Relationships to Disclose
 
Katayoun Rezvani
No Relationships to Disclose
 
Elizabeth J. Shpall
No Relationships to Disclose
 
Doris Soebbing
No Relationships to Disclose
 
Richard E. Champlin
No Relationships to Disclose
 
Dean Anthony Lee
Leadership - Cyto-Sen Therapeutics
Stock and Other Ownership Interests - Courier Therapeutics; Cyto-Sen Therapeutics
Honoraria - Miltenyi Biotec
Consulting or Advisory Role - Courier Therapeutics; Cyto-Sen Therapeutics; Intellia Therapeutics; Jazz Pharmaceuticals; Merck Sharp & Dohme; Shire; ZIOPHARM Oncology
Patents, Royalties, Other Intellectual Property - US 60/925,830, PCT/US2008/061342 US 62/404,520 US 62/623,682 US 18/20,187
Travel, Accommodations, Expenses - Cyto-Sen Therapeutics; Merck Sharp & Dohme; Shire